awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q28075305-0B1DCEB6-98E3-4011-99F7-313CA4FAC5A0
Q28075305-0B1DCEB6-98E3-4011-99F7-313CA4FAC5A0
BestRank
Statement
http://www.wikidata.org/entity/statement/Q28075305-0B1DCEB6-98E3-4011-99F7-313CA4FAC5A0
Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma
P2860
Q28075305-0B1DCEB6-98E3-4011-99F7-313CA4FAC5A0
BestRank
Statement
http://www.wikidata.org/entity/statement/Q28075305-0B1DCEB6-98E3-4011-99F7-313CA4FAC5A0
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
0ffb4b837aa8000714bda514ee36c3c83ba7eba2
P2860
A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.